Beximco Pharmaceuticals ADR

Hearings on two lawsuits challenging orders by the securities regulator BSEC will not begin until after April 18 because of the court vacation of the High Court Division of Bangladesh. One case challenges the proposed appointment of nine independent non-executive directors (Case No. 525/2025), and the other challenges the order to hold a meeting to appoint these directors (Case No. 1243/2026). » Altro su de.investing.com

Beximco Pharmaceuticals is temporarily suspending trading of its Global Depositary Receipts (GDRs) on the AIM in London from 2 January 2026 because it cannot publish its annual results for the year ended 30 June 2025 on time. The delay is caused by a postponement in convening a board meeting, due to a pending High Court proceeding in Bangladesh concerning the appointment of additional independent directors; the case must be reheard after the judicial benches are reconstituted. The company expects a court decision no earlier than January 2026 and stresses that its shares will continue to be traded on the Dhaka Stock Exchange and the Chittagong Stock Exchange and that reportable developments will be announced. » Altro su de.investing.com

Beximco Pharmaceuticals has applied to Bangladesh’s securities regulator (BSEC) for an extension to publish its Q1 figures until 30 September 2025. The reason is an ongoing legal dispute over the composition of the board after the BSEC proposed appointing nine additional independent non-executive directors. The case is currently before the High Court, and a decision is not expected before the end of the month; this is Beximco’s third postponement request in 2025. » Altro su de.investing.com